- Details
- Tanya Dorff and Alicia Morgans discuss the importance of multidisciplinary care teams for patients with bone metastatic castration-resistant prostate cancer (mCRPC). The pair talk about the need for clear communication between physicians, radiation oncologists, and nuclear medicine physicians on the team, as well as the importance of the nursing and imaging staff. Dr. Dorff also stresses the impor...
|
- Details
- Philip Koo and Alicia Morgans discuss the evolving role of nuclear medicine in the multidisciplinary care of patients receiving radium-223 for metastatic CRPC (Castration-Resistant Prostate Cancer). Dr. Koo advocates for the emergence of "nuclear oncology" as the fourth pillar in comprehensive cancer programs, emphasizing the need for enhanced communication and collaboration among medical oncologi...
|
- Details
- In this conversation, Fred Saad and Alicia Morgans discuss treatment sequencing in terms of Radium-223 when treating a minimally symptomatic patient or a maximally symptomatic patient. Biographies: Fred Saad, MD, FRCS, Professor and Chief of Urology, Director of GU Oncology, Raymond Garneau Chair in Prostate Cancer, University of Montreal Hospital Centre (CHUM), Director, Prostate Cancer Research,...
|
- Details
- In this UroToday discussion between Alicia Morgans and Celestia (Tia) Higano, the pair discuss the REASSURE trial, a phase IV study to further evaluate the safety of radium-223 in the long-term setting. REASSURE is a real-world analysis of pain efficacy of radium-223 treatment among patients with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. Dr. Higano hi...
|
- Details
- Real-World Safety and Effectiveness of Radium-223 in Japanese Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastasis: Exploratory Analysis, Based on the Results of Post-Marketing Surveillance, According to Prior Chemotherapy Status - Beyond the Abstract. Biographies: Hirotsugu Uemura, Urologist, Chief Professor, Urology Department, Kindai University, Japan Related Content: R...
|
- Details
- In this conversation Tanya Dorff and Alicia Morgans discuss the guidance coming from the NCCN on the use of radium-223 in the metastatic castration-resistant prostate cancer setting, including choosing the right patient for this drug, factors to consider, and the timing of this therapy. As lines of therapy become more complicated with many castration-resistant drugs moving to the hormone-sensitive...
|
- Details
- Brenda Martone and Alicia Morgans discuss the positioning of radium-223 in the treatment of patients with bone-only mCRPC. Brenda emphasizes that radium-223 is approved for symptomatic bone-only disease and that this includes many symptoms including fatigue, loss of appetite, and others that are not limited to bone-related pain. This is approved in a broad population and needs to be considered in...
|
- Details
- Alicia Morgans engages with Michael Morris to delve into the rapidly evolving landscape of radiopharmaceuticals in prostate cancer treatment, highlighting the significance of the VISION data and existing therapies like radium-223. Dr. Morris outlines that the abundance of radiopharmaceutical tools is a "good problem to have," emphasizing that these agents are not one-size-fits-all but have unique...
|
- Details
- Bone strengthening agents such as bisphosphonates or the RANKL-targeting antibody denosumab reduced the bone loss associated with androgen deprivation therapy (ADT) and prevent skeletal-related events in castration resistant prostate cancer (CRPC). The use of these agents is recommended in CRPC by many guidelines. The randomized phase III EORTC-1333-GUCG also known as the PEACE-III trial, compares...
|
- Details
- Benjamin Maughan, MD joins Charles Ryan, MD in a discussion on investigational therapy currently being testing of a combination of enzalutamide and radium-223 compared to enzalutamide alone, both FDA-approved therapies for metastatic castration-resistant prostate cancer (mCRPC). This was a randomized study, patients were randomized to standard of care and enzalutamide or six cycles of radium plus...
|
